Paediatric Medicines in Europe: The Paediatric Regulation—Is It Time for Reform?

Abstract

Objectives: In this paper, we investigated the effects of the European Paediatric Regulation (EC) N° 1901/2006 with respect to satisfying the paediatric therapeutic needs, assessed in terms of the increased number of paediatric medicinal products, new therapeutic indications in specific high-need conditions (neonates, oncology, rare disease, etc.) and increased number of paediatric clinical studies supporting the marketing authorisation.Methods: We analysed the paediatric medicinal products approved by the European Medicines Agency in the period January 2007-December 2019, by collecting the following data: year of approval, active substance, legal basis for the marketing authorisation, type of medicinal product (i.e., chemical, biological, or ATMP), orphan drug status, paediatric indication, Anatomical Therapeutic Chemical code (first-level), number and type of paediatric studies. Data were compared with similar data collected in the period 1996–2006.Results: In the period January 1996–December 2019, in a total of 1,190 medicinal products and 843 active substances, 34 and 38%, respectively, were paediatric. In the two periods, before and after the Paediatric Regulation implementation, the paediatric/total medicinal products ratio was constant while the paediatric/total active substances ratio decreased. Moreover, excluding generics and biosimilars, a total of 106 and 175 paediatric medicines were granted a new paediatric indication, dosage or age group in the two periods; out of 175, 128 paediatric medicines had an approved Paediatric Investigational Plan. The remaining 47 were approved without an approved Paediatric Investigational Plan, following the provisions of Directive 2001/83/EC and repurposing an off-patent drug. The analysis of the clinical studies revealed that drugs with a Paediatric Investigational Plan were supported by 3.5 studies/drug while drugs without a Paediatric Investigational Plan were supported by only 1.6 studies/drug.Discussion: This report confirms that the expectations of the European Paediatric Regulation (EC) N° 1901/2006 have been mainly satisfied. However, the reasons for the limited development of paediatric medicines in Europe, should be further discussed, taking advantage of recent initiatives in the regulatory field, such as the Action Plan on Paediatrics, and the open consultation on EU Pharmaceutical Strategy.

ADV6209 for Premedication in Pediatric Anesthesia: A Double-Blinded, Randomized Controlled Trial

“…While the European Union mandates approval of all drugs for all age groups, there is no denying that this goal has yet to be achieved [ 22 , 23 , 24 , 25 , 26 ]. Hence the continuing need for pediatric practitioners to administer drugs off-label does carry a risk of forensic implications.…”

Patient attrition in Molecular Tumour Boards: A Review

“…Unsurprisingly, a common barrier to paediatric studies was gaining access to treatment options. Though drug development has increased in this area 78 further work is being done in cancers where presentation in adults differs to children or paediatric-specific cancers 79 .…”

Evidenzbasierte Off-label-Anwendung von Arzneimitteln bei Kindern und Jugendlichen

“…Die pädiatrischen Initiativen haben in den letzten 20 Jahren eine Zunahme von AM-Studien bei Kindern bewirkt und vermehrt zu pädiatrischen Zulassungen, neuen pädiatrischen Indikationen und pädiatrischen Darreichungsformen geführt [4,24]. Dies hat also punktuell bereits Verbesserungen der AM-Versorgung von Kindern bewirkt, die weitreichenden Defizite sind aber bei Weitem noch nicht ausgeglichen [23]. Gründe sind, dass Schwerpunkte der AM-Entwicklungen primär durch den Bedarf bei Erwachsenen bestimmt sind, während manche therapeutischen Bedürfnisse von Kindern kaum adressiert werden.…”